Genevoyager has announced the opening of its contract development and manufacturing organisation (CDMO) facility to manufacture gene therapy products.

The new cGMP [current good manufacturing practice] compliant facility is equipped with the company’s One-Bac 4.0 System with Sf-RVF cell line and adheres to National Medical Products Administration, Food and Drug Administration and European Medicines Agency standards. 

Spread over 68,000ft², the plant is designed to support the development, production and scaling of adeno-associated virus (AAV) gene therapy products.

Genevoyager will offer development and manufacturing services for AAV, oncolytic viruses, lentivirus and recombinant proteins.

The company’s One-Bac 4.0 system is an insect baculovirus platform that introduces a new approach to regulating AAV expression cassettes.

It intends to overcome existing issues in AAV-based gene therapy products by delivering stability and increased yields during scale-up production, ranging from 1E+15 to 5E+15 vg/L for volumes between 500L and 2,000L.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The system also guarantees safety by reducing impurities and eliminating replication-competent AAV (rcAAV).

It offers increased infectivity and full capsid ratios of more than 70% in crude harvest.

The system could also make gene therapy more easily accessible by cutting down manufacturing expenses, thereby facilitating an affordable pricing model that can meet the medical needs of a wider patient population.

Through the CDMO facility opening, the company aims to advance healthcare through gene therapy solutions.

Genevoyager CEO Dr Xiaobing He stated: “We are thrilled to unveil our state-of-the-art CDMO facility.

“With our revolutionary insect baculovirus system addressing the complexities of AAV manufacturing, particularly for systemically administered gene therapy products, we are forging a pathway to provide high-quality and affordable gene therapies to patients worldwide.”

The company provides contract research organisation/CDMO services for gene therapy products and has a technology platform for large-scale AAV production and cGMP facilities.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.